title: Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach.
abstract: Metabolomics represents an emerging and powerful discipline concerned with the comprehensive analysis of small molecules and provides a powerful approach to discover biomarkers in biological systems. Recent development of biomarkers for diagnosis and therapeutic monitoring of liver-stagnation and spleen-deficiency syndrome (LSS)-type disease remains challenging. This study was undertaken to discover novel potential biomarkers for the non-invasive early diagnosis of human LSS. Urine samples which are potentially a rich source of metabolites were collected from patients with LSS, together with healthy control samples. Metabolite profiling was performed by ultra-performance liquid-chromatography/electrospray-ionization synapt high-definition mass spectrometry (UPLC-Q-TOF-HDMS) in conjunction with multivariate data analysis and ingenuity pathway analysis that were used to select the metabolites to be used for the non-invasive diagnosis of LSS. Twelve urinary differential metabolites contributing to the complete separation of LSS patients from matched healthy controls were identified involving several key metabolic pathways such as pentose and glucuronate interconversions, ascorbate, aldarate, cysteine, methionine, tyrosine, tryptophan, amino sugar and nucleotide sugar metabolism. More importantly, of the 12 differential metabolites, 4 metabolite markers, prolylhydroxyproline, L-homocystine, 2-octenoylcarnitine and α-N-phenylacetyl-L-glutamine, were effective for the diagnosis of human LSS, with an achieved sensitivity of 93.0%. These results demonstrate that robust metabolomics has the potential as a non-invasive strategy and promising screening tool to evaluate the potential of these metabolites in the early diagnosis of LSS patients and provides new insight into pathophysiological mechanisms.
authors.affiliation: National TCM Key Lab of Serum Pharmacochemistry, Heilongjiang University of Chinese Medicine, Harbin, China.
authors.forename: Aihua
authors.initials: A
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Ying
authors.initials: Y
authors.lastname: Han
authors.forename: Ye
authors.initials: Y
authors.lastname: Yuan
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Gaochen
authors.initials: G
authors.lastname: Song
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Yuan
authors.forename: Miao
authors.initials: M
authors.lastname: Zhang
authors.forename: Ning
authors.initials: N
authors.lastname: Xie
authors.forename: Xijun
authors.initials: X
authors.lastname: Wang
mesh_terms: D015415:Biomarkers / Q000652:urine*; D002851:Chromatography, High Pressure Liquid; D002853:Chromatography, Liquid; D006801:Humans; D008107:Liver Diseases / Q000175:diagnosis* / Q000652:urine; D053858:Metabolic Networks and Pathways; D055432:Metabolomics / Q000379:methods*; D010363:Pattern Recognition, Automated; D025341:Principal Component Analysis; D021241:Spectrometry, Mass, Electrospray Ionization
chemical_list: D015415:Biomarkers